ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra rare genetic diseases. The company develops and commercializes approved therapies and product candidates that address diseases with high unmet medical need and clear biology. Its product modalities include biologics, small molecules, adeno associated virus gene therapy, and nucleic acid candidates. Ultragenyx focuses on rare and ultra rare indications where approved therapies are lacking and the underlying disease pathways are well understood.

ultragenyx generates revenue primarily from the sale of its approved products Crysvita, Mepsevii, Dojolvi, and Evkeeza. Revenue also arises from collaboration agreements, licensing, royalties, and milestone payments with partners such as Kyowa Kirin, Regeneron, Saint Louis University, Baylor Research Institute, Mereo, GeneTx, Abeona, and REGENXBIO. For the year ended December 31, 2025, 45% of total revenues were generated by the collaboration partner Kyowa Kirin. The company sells its products through drug wholesalers and retail pharmacy distributors in North America, Europe, Latin America, and selected international markets.

ultragenyx competes in the rare disease biopharmaceutical sector where it faces competition from other companies developing therapies for similar indications. For X Linked hypophosphatemia and tumor induced osteomalacia, the main competition comes from off label phosphate and vitamin D therapy and potential future gene therapy approaches. For mucopolysaccharidosis VII, there are currently no approved competitors although enzyme replacement therapy and gene therapy programs are under investigation elsewhere. For long chain fatty acid oxidation disorders, the standard of care includes diet therapy and medium chain triglyceride oil and generic versions of triheptanoin could enter the market. For homozygous familial hypercholesterolemia, competitors include existing lipid lowering agents such as statins, fibrates, ezetimibe, evolocumab, lomitapide and emerging therapies targeting ANGPTL3 from companies like Arrowhead Pharmaceuticals, Eli Lilly, Dicerna, Novo Nordisk and CRISPR Therapeutics. For Angelman syndrome, there are no approved drugs and competitors include antisense oligonucleotide programs from Ionis, Oak Hill Bio, Neuren Pharmaceuticals and MavriX Bio. For Sanfilippo syndrome type A, there are no approved pharmacologic treatments and competitors include gene therapy candidates such as EGT 101, OTL 201 and enzyme replacement therapies under study. For glycogen storage disease type Ia, there are no pharmacologic treatments and competitors include gene editing programs like BEAM 301 and mRNA therapies such as mRNA 3745 from Moderna. For ornithine transcarbamylase deficiency, current treatments involve nitrogen scavenger drugs and competitors include mRNA and gene therapy approaches from Arcturus Therapeutics, Bloomsbury, iECURE and Camp 4. For Wilson disease, there are no approved treatments and competitors include chelator therapies such as ALXN 1840 from Monopar Therapeutics and gene therapy candidates like LY M003 from LingYiMed. For osteogenesis imperfecta, there are no approved drugs and competitors include off label bisphosphonate use and anti sclerostin antibodies such as romosozumab from Amgen.

ultragenyx serves collaboration partners, drug wholesalers, and retail pharmacy distributors. Key collaboration partners include Kyowa Kirin Co., Ltd., Regeneron, Saint Louis University, Baylor Research Institute, Mereo, GeneTx, Abeona, and REGENXBIO. The company also relies on drug wholesalers and retail pharmacy distributors to reach patients and healthcare providers in its markets.